Oxford BioTherapeutics enters into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer

CAR-T Digest - August 2020

Weekly Digest - March 2025

19 Mar 2025: Oxford BioTherapeutics enters into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer

Oxford BioTherapeutics (OBT) has partnered with Roche in a multi-year collaboration to discover novel antibody-based cancer therapeutics, combining OBT’s OGAP Verify platform with Roche’s drug development expertise
Under the agreement, OBT will receive up to US$36 million in upfront payments, with potential milestone payments exceeding US$1 billion, along with royalties on net sales of resulting products
The collaboration will utilize OBT’s enhanced OGAP Verify discovery platform, which offers greater sensitivity in identifying promising oncology targets for drug development
The partnership aims to accelerate the development of innovative cancer therapies, leveraging OBT’s platform and Roche’s strengths in drug development and diagnostics to address significant unmet needs in oncology